Galenica S.A.

Galenica S.A. company information, Employees & Contact Information

Explore related pages

Related company profiles:

Founded in 1974, Galenica is a leading Greek pharmaceutical company dedicated to providing innovative therapeutic solutions across prescription and over-the-counter drugs, supplements, and medical devices. For over four decades, we have advanced human health through scientific innovation and a commitment to quality. Our production facilities in Chalkida and Kryoneri are EU GMP-certified and FDA-approved, producing various pharmaceutical forms including injectables, pills, and liquids. We adhere to strict safety, quality, and environmental standards, ensuring our products are trusted by healthcare providers and patients. Our core business includes contract manufacturing, in-licensing, and exports, and we proudly collaborate with trusted partners worldwide to uphold transparency, ethics, and sustainability. With a distribution network spanning over 35 countries across Europe, Africa, Asia, North America, South America, and the Middle East, we are constantly expanding our reach. Sustainability is a key pillar of our philosophy, and we continuously work to reduce our environmental footprint through renewable energy usage, waste reduction, and lower greenhouse gas emissions. At Galenica, our human-centric approach leads us to enhance lives across various therapeutic categories. We strive to deliver healthcare solutions that improve quality of life, offering fast, effective relief. Guided by a global vision and an unwavering commitment to excellence, we are shaping the future of healthcare.

Company Details

Employees
183
Founded
-
Address
4, Eleftherias Street,greece
Phone
+30 210 5281700
Email
co****@****nica.gr
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Kifissia, Attika
Looking for a particular Galenica S.A. employee's phone or email?

Galenica S.a. Questions

News

Galenica AG Reports Robust Q3 Growth and Raises Guidance - TipRanks

Galenica AG Reports Robust Q3 Growth and Raises Guidance TipRanks

Baker McKenzie Advises UBS on the Financing of Galenica’s Acquisition of the Labor Team Group - Baker McKenzie

Baker McKenzie Advises UBS on the Financing of Galenica’s Acquisition of the Labor Team Group Baker McKenzie

While institutions own 45% of Galenica AG (VTX:GALE), retail investors are its largest shareholders with 55% ownership - simplywall.st

While institutions own 45% of Galenica AG (VTX:GALE), retail investors are its largest shareholders with 55% ownership simplywall.st

Galenica AG News Today: Stock Surges Amid Acquisition Speculation - Meyka

Galenica AG News Today: Stock Surges Amid Acquisition Speculation Meyka

Switzerland: Galenica enters diagnostics market with acquisition of Labor Team Group - Investors in Healthcare

Switzerland: Galenica enters diagnostics market with acquisition of Labor Team Group Investors in Healthcare

Planzer and Galenica launch Health Supply AG - Switzerland Global Enterprise

Planzer and Galenica launch Health Supply AG Switzerland Global Enterprise

Here's Why Galenica AG's (VTX:GALE) CEO May Have Their Pay Bumped Up - simplywall.st

Here's Why Galenica AG's (VTX:GALE) CEO May Have Their Pay Bumped Up simplywall.st

Pharmaceuticals: Galenica sets itself higher profit target after half-year | blue News - bluewin E-Mail

Pharmaceuticals: Galenica sets itself higher profit target after half-year | blue News bluewin E-Mail

3 Q&A interview with Kristina Thored, Vice President CDMO, MVA member Galenica - mva.org

3 Q&A interview with Kristina Thored, Vice President CDMO, MVA member Galenica mva.org

Despite Its High P/E Ratio, Is Galenica AG (VTX:GALE) Still Undervalued? - Yahoo Finance

Despite Its High P/E Ratio, Is Galenica AG (VTX:GALE) Still Undervalued? Yahoo Finance

Galenica Group focuses on pharmaceuticals as it becomes Vifor Pharma Group - News-Medical

Galenica Group focuses on pharmaceuticals as it becomes Vifor Pharma Group News-Medical

All change at Galenica with split, IPO and name change - The Pharma Letter

All change at Galenica with split, IPO and name change The Pharma Letter

Galenica Sante raises $1.9 billion in Europe's biggest IPO this year - Reuters

Galenica Sante raises $1.9 billion in Europe's biggest IPO this year Reuters

Galenica Group to Acquire Relypsa for $1.53B - Genetic Engineering and Biotechnology News

Galenica Group to Acquire Relypsa for $1.53B Genetic Engineering and Biotechnology News

Galenica and Relypsa Announce Agreement for Galenica to Acquire Relypsa - GlobeNewswire

Galenica and Relypsa Announce Agreement for Galenica to Acquire Relypsa GlobeNewswire

Vifor Pharma to top cardio-renal care after Galenica completes Relyapsa acquisition - European Pharmaceutical Review

Vifor Pharma to top cardio-renal care after Galenica completes Relyapsa acquisition European Pharmaceutical Review

Galenica snaps up Relypsa and its Veltassa med for $1.53B in march toward Vifor spinoff - Fierce Pharma

Galenica snaps up Relypsa and its Veltassa med for $1.53B in march toward Vifor spinoff Fierce Pharma

Relypsa finally finds a buyer as Veltassa partner Galenica coughs up $1.5B - Fierce Biotech

Relypsa finally finds a buyer as Veltassa partner Galenica coughs up $1.5B Fierce Biotech

Galenica AG Unveils Innovative Pharmacy Concept to Enhance Healthcare Services - TipRanks

Galenica AG Unveils Innovative Pharmacy Concept to Enhance Healthcare Services TipRanks

The Returns At Galenica (VTX:GALE) Aren't Growing - simplywall.st

The Returns At Galenica (VTX:GALE) Aren't Growing simplywall.st

Relypsa Inc: RLYP Stock Pops 60% on Galenica Buyout Bid - Nasdaq

Relypsa Inc: RLYP Stock Pops 60% on Galenica Buyout Bid Nasdaq

Galenica Group strengthens management team - PMLiVE

Galenica Group strengthens management team PMLiVE

Galenica (VTX:GALE) shareholders have earned a 9.4% CAGR over the last five years - simplywall.st

Galenica (VTX:GALE) shareholders have earned a 9.4% CAGR over the last five years simplywall.st

Galenica confident of meeting annual targets after strong half-year - SWI swissinfo.ch

Galenica confident of meeting annual targets after strong half-year SWI swissinfo.ch

First Galenica block ends three times covered - GlobalCapital

First Galenica block ends three times covered GlobalCapital

EU clears Fresenius, Galenica pharma joint venture - Reuters

EU clears Fresenius, Galenica pharma joint venture Reuters

Apotheken-Netzwerk Galenica fühlt mit Zeam GenZ-Puls - markt-kom.com

Apotheken-Netzwerk Galenica fühlt mit Zeam GenZ-Puls markt-kom.com

Swiss Firm Galenica Group Buys Aspreva Pharmaceuticals For US$26.00 Per Share In Cash - Update - RTTNews

Swiss Firm Galenica Group Buys Aspreva Pharmaceuticals For US$26.00 Per Share In Cash - Update RTTNews

Bankruptcy in "Galenica" due to a tax debt of 2,6 million - vijesti.me

Bankruptcy in "Galenica" due to a tax debt of 2,6 million vijesti.me

The medicines arrive by the end of August, the debt to Galenica remains - vijesti.me

The medicines arrive by the end of August, the debt to Galenica remains vijesti.me

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant